Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
COEPW
Upturn stock ratingUpturn stock rating

Coeptis Therapeutics Holdings Inc (COEPW)

Upturn stock ratingUpturn stock rating
$0.03
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: COEPW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.03
high$

Analysis of Past Performance

Type Stock
Historic Profit -89.12%
Avg. Invested days 14
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -0.59
52 Weeks Range 0.00 - 0.05
Updated Date 02/25/2025
52 Weeks Range 0.00 - 0.05
Updated Date 02/25/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -245.55%
Return on Equity (TTM) -1449.7%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 12704886
Shares Outstanding -
Shares Floating 12704886
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Coeptis Therapeutics Holdings Inc

stock logo

Company Overview

overview logo History and Background

Coeptis Therapeutics Holdings, Inc. is a pharmaceutical company focused on developing innovative therapies. Founded in 2013, the company has focused on acquiring and developing assets in oncology and other areas. Milestones include acquiring companies to expand portfolio and progress clinical trials. The company has shifted strategy over time with key licensing agreements.

business area logo Core Business Areas

  • Drug Development: Focuses on developing and commercializing therapies for cancer and other diseases. Utilizes proprietary technology platforms.
  • CD38-Directed Therapeutic Antibody: This segment focuses on drug candidate, CD38-GEAR-NK cell therapy. The drug target is CD38, found in abundance in myeloma tumor cells as well as solid tumors.

leadership logo Leadership and Structure

The company's leadership team consists of a CEO, CFO, and other key executives. The organizational structure includes departments for research and development, clinical operations, and business development.

Top Products and Market Share

overview logo Key Offerings

  • CD38-GEAR-NK: CD38-GEAR-NK cell therapy is Coeptisu2019 drug candidate that is designed to overcome key limitations of existing CD38-targeted therapies. Coeptis Therapeutics Holdings Inc is currently in clinical trials. Competitors include Darzalex (daratumumab) from Johnson & Johnson.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and regulated, with significant investment in research and development. The industry includes major players such as Johnson and Johnson (JNJ) and Pfizer (PFE). The market for cancer therapies is growing due to the increasing incidence of cancer worldwide.

Positioning

Coeptis Therapeutics Holdings Inc is a smaller player in the pharmaceutical industry, focused on niche markets with innovative therapies. Competitive advantages include proprietary technology platforms and strategic partnerships.

Total Addressable Market (TAM)

The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Coeptis Therapeutics Holdings Inc aims to capture a portion of this market through the development and commercialization of its therapies.

Upturn SWOT Analysis

Strengths

  • Innovative Technology
  • Experienced Management Team
  • Strategic Partnerships
  • Niche Market Focus

Weaknesses

  • Limited Financial Resources
  • Early Stage Pipeline
  • Dependence on Key Personnel
  • Limited Market Presence

Opportunities

  • Expanding into New Markets
  • Acquiring Complementary Technologies
  • Securing Regulatory Approvals
  • Forming Strategic Alliances

Threats

  • Competition from Larger Companies
  • Regulatory Hurdles
  • Patent Infringement
  • Clinical Trial Failures

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • PFE
  • MRK
  • BMY
  • GILD

Competitive Landscape

Coeptis Therapeutics Holdings Inc faces significant competition from larger pharmaceutical companies with greater resources. The company differentiates itself through innovative technologies and niche market focus.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data unavailable.

Future Projections: Future growth projections data unavailable.

Recent Initiatives: Recent initiatives include focusing on CD38-GEAR-NK cell therapy and other asset acquisitions.

Summary

Coeptis Therapeutics Holdings Inc is a development-stage pharmaceutical company focused on developing innovative therapies. The company's strengths lie in its innovative technology and strategic partnerships. Weaknesses include limited financial resources and early-stage pipeline. It needs to secure funding and achieve clinical trial success to fully realize potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Market Reports

Disclaimers:

The data provided is for informational purposes only and should not be considered investment advice. Market share is an estimate and may vary based on source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Coeptis Therapeutics Holdings Inc

Exchange NASDAQ
Headquaters Wexford, PA, United States
IPO Launch date 2020-12-17
Co-Founder, Chairman, CEO & Pres Mr. David Mehalick
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.